Additionally, in a study, after resistance to RET inhibitors, 15% of RET fusion NSCLC patients developed MET gene amplification, while only 10% of patients developed resistance through secondary mutations in the RET gene, demonstrating that MET gene amplification is also one of the most common causes of resistance to RET inhibitors (77). The gene discussed is RET; the disease is non-small cell lung carcinoma.